![Pille HARRISON | VP | MD, DPhil, MRCP (UK) | Alpine Immune Sciences, Washington | Clinical Development Pille HARRISON | VP | MD, DPhil, MRCP (UK) | Alpine Immune Sciences, Washington | Clinical Development](https://www.researchgate.net/profile/Pille-Harrison/publication/321019759/figure/tbl1/AS:1010231840604161@1617869448281/Summary-of-Exposure-and-Safety-Outcomes-Per-100-PYE_Q320.jpg)
Pille HARRISON | VP | MD, DPhil, MRCP (UK) | Alpine Immune Sciences, Washington | Clinical Development
![Pille HARRISON | VP | MD, DPhil, MRCP (UK) | Alpine Immune Sciences, Washington | Clinical Development Pille HARRISON | VP | MD, DPhil, MRCP (UK) | Alpine Immune Sciences, Washington | Clinical Development](https://www.researchgate.net/profile/Pille-Harrison/publication/321019741/figure/tbl1/AS:938590179696640@1600788745529/DARWIN-2-safety-overview_Q320.jpg)
Pille HARRISON | VP | MD, DPhil, MRCP (UK) | Alpine Immune Sciences, Washington | Clinical Development
![Pille HARRISON | VP | MD, DPhil, MRCP (UK) | Alpine Immune Sciences, Washington | Clinical Development Pille HARRISON | VP | MD, DPhil, MRCP (UK) | Alpine Immune Sciences, Washington | Clinical Development](https://www.researchgate.net/profile/Pille-Harrison/publication/321019759/figure/tbl2/AS:1010231840604163@1617869448313/Treatment-Emergent-Laboratory-Abnormalities-Per-100-PYE_Q320.jpg)
Pille HARRISON | VP | MD, DPhil, MRCP (UK) | Alpine Immune Sciences, Washington | Clinical Development
![Pille HARRISON | VP | MD, DPhil, MRCP (UK) | Alpine Immune Sciences, Washington | Clinical Development Pille HARRISON | VP | MD, DPhil, MRCP (UK) | Alpine Immune Sciences, Washington | Clinical Development](https://www.researchgate.net/publication/323967829/figure/fig1/AS:963126119895050@1606638569605/Patient-Global-scores-methotrexate-MTX-add-on-a-and-monotherapy-b-Patient-Pain_Q320.jpg)